SEO Services, technology and web design

Written by Adv. Vikram Swaran Singh Chadha The Drug Information Association’s (DIA’s) 44th Annual Meeting will feature more than 370 sessions and 30 tutorials focusing on issues affecting global drug discovery and development, including hot topic sessions on:

Adaptive Clinical Designs/Adaptive Methods
Approval Pathways for Products to Treat Rare Diseases
Biotechnology
Clinical and Regulatory Considerations for Personalized Medicines
Combination Device and Therapeutic Products
Critical Path Initiative
Multinational Clinical Trials including Developing Countries
Patient Recruitment and Retention
Pediatrics

Safety is always going to be a hot topic and with the FDA and EMEA both paying increased attention to the issue, it is especially so today, explains Annual Meeting Program Chair Jeffrey Sherman, MD, FACP.

Safety is always going to be a hot topic and with the FDA and EMEA both paying increased attention to the issue, it is especially so today
This year’s multi-track plenary session, The Impact of FDAAA on Drug Safety, (Tuesday, June 24 from 8:00-9:30 am) will feature speakers from US and European regulatory agencies, the Reagan Udall Foundation, PhRMA, and other organizations to discuss their goals and experiences with implementation of the Food and Drug Administration Amendments Act of 2007 (FDAAA). Attendees can submit questions to the panel by Friday, June 20 to FDAAAondrugsafetypanel @ diahome.org; Subject: Questions for the Panel.

The Venture Capital Roundtable: Biotechnology and Pharmaceutical/Health Care IT on Wednesday, June 25, will be of interest to many Boston-based companies, as will A Device Primer: IDEs, 510(k)s, PMAs, and Beyond on Sunday, June 22. Also, the FDA Center for Drug Evaluation and Review (CDER) will hold its two-part Annual Town Hall-an interactive session where attendees can submit questions to senior CDER leaders–on Thursday, June 26.

As an international organization, global drug development is also a key focus of the Annual Meeting. This year’s event will include more than 100 sessions on issues affecting key regions of the world, including:


China - 18 sessions
India - 12 sessions
Japan - 23 sessions
Taiwan - 4 sessions
Vietnam - 1 session
Latin America- 11 sessions
Canada - 4 sessions
Western Europe - 27 sessions
Eastern Europe - 2 sessions

In addition, speakers from the following regulatory agencies will present at the Annual Meeting:


ANMAT Ministry of Health (Argentina)
ANMAT Ministry of Health (Brazil)
Center for Drug Evaluation (Taiwan)
EMEA (Europe)
FDA MOPH (Thailand)
Health Canada
MHRA (UK)
MHLW (Japan)
Ministry of Health, Welfare and Sport (Netherlands)
PMDA (Japan)
SFDA (China)
State Institute for Drug Control (Czech Republic)
US FDA
WHO (Switzerland)

Started as a free lance writer earlier for Maharashtra Herald Newspaper, then with the Pune-Mid-Day. Have also contributed for articles on websites